Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010146338) AMIDO-ISOTHIAZOLE COMPOUNDS AND THEIR USE AS INHIBITORS OF 11BETA-HSD1 FOR THE TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/146338 International Application No.: PCT/GB2010/001155
Publication Date: 23.12.2010 International Filing Date: 14.06.2010
IPC:
C07D 417/06 (2006.01) ,C07D 417/14 (2006.01) ,A61K 31/435 (2006.01) ,A61K 31/425 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
06
linked by a carbon chain containing only aliphatic carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
Applicants:
WEBSTER, Scott, Peter [GB/GB]; GB (UsOnly)
SECKL, Jonathan, Robert [GB/GB]; GB (UsOnly)
WALKER, Brian, Robert [GB/GB]; GB (UsOnly)
WARD, Peter [GB/GB]; GB (UsOnly)
PALLIN, Thomas, David [GB/GB]; GB (UsOnly)
DYKE, Hazel, Joan [GB/GB]; GB (UsOnly)
PERRIOR, Trevor, Robert [GB/GB]; GB (UsOnly)
THE UNIVERSITY OF EDINBURGH [GB/GB]; Old College South Bridge Edinburgh EH8 9YL, GB (AllExceptUS)
Inventors:
WEBSTER, Scott, Peter; GB
SECKL, Jonathan, Robert; GB
WALKER, Brian, Robert; GB
WARD, Peter; GB
PALLIN, Thomas, David; GB
DYKE, Hazel, Joan; GB
PERRIOR, Trevor, Robert; GB
Agent:
WYTENBURG, Wilhelmus; MEWBURN ELLIS LLP 33 Gutter Lane London EC2V 8AS, GB
Priority Data:
61/186,96315.06.2009US
Title (EN) AMIDO-ISOTHIAZOLE COMPOUNDS AND THEIR USE AS INHIBITORS OF 11BETA-HSD1 FOR THE TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS
(FR) COMPOSÉS AMIDO-ISOTHIAZOLE ET LEUR UTILISATION COMME INHIBITEURS DE LA 11 Β-HSD1 DANS LE TRAITEMENT DU SYNDROME MÉTABOLIQUE ET DES TROUBLES APPARENTÉS
Abstract:
(EN) The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
(FR) La présente invention concerne en général le domaine des composés thérapeutiques. La présente invention concerne plus particulièrement certains composés amido-isothiazole qui, entre autres, inhibent la 11 β-hydroxystéroïde déshydrogénase de type 1 (11 β-HSD1). La présente invention concerne également des compositions pharmaceutiques comprenant de tels composés, et l'utilisation de tels composés et compositions, à la fois in vitro et in vivo, pour inhiber la 11 β-hydroxystéroïde déshydrogénase de type 1 ; pour traiter des troubles qui sont améliorés par l'inhibition de la 11 β-hydroxystéroïde déshydrogénase de type 1 ; pour traiter le syndrome métabolique, comprenant des troubles tels que le diabète de type 2 et l'obésité, et des troubles associés comprenant la résistance à l'insuline, l'hypertension, des troubles lipidiques et des troubles cardiovasculaires tels que la cardiopathie (coronaropathie) ischémique ; pour traiter des troubles du SNC tels qu'un trouble cognitif léger ou la démence précoce, y compris la maladie d'Alzheimer ; etc.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)